Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicines Bill to be Fast-tracked With the Completion of the Senate Committees (Phillipines)

This article was originally published in PharmAsia News

Executive Summary

Philippines Senator Mar Roxas on Sunday said the approval of a proposed "cheaper medicines" bill could be fast-tracked once the composition of the Senate Committees on Trade and on Health is completed, which he predicted to happen this week. "We're just waiting for the committees to be fully constituted, and then we'll start the hearings as soon as possible," he said. Roxas said that the battle for flexibility in patent laws on medicines is an international battle. "In the international front, steps are being taken to make life-saving medicines affordable and available to all. We must not be left behind," he stated. Roxas said he was buoyed by an Indian court's recent decision to reject patent infringement claims by Novartis AG for its cancer medicine Glivec. The bill also provides a legal mechanism for the importation of cheaper drugs whose patents have not expired locally, otherwise known as parallel importation. The bill also provides an "early working doctrine" where generic drug manufacturers are allowed to experiment, produce and register patented drugs even prior to expiration of their patents. (Click here for more

You may also be interested in...



Bayer's Finerenone Hints Positive In Diabetic Kidney Disease

The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

US FDA Announces Plans To Resume Domestic Inspections

Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.

UsernamePublicRestriction

Register

RS150180

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel